Hispidulin Suppresses Hepatocellular Carcinoma Proliferation by Targeting PI3K-Akt Pathway: A Network Pharmacology and Experimental Validation Study
Journal of Hepatocellular Carcinoma · 2026-09 · Volume 13 · 1-15
DOI: 10.2147/jhc.s613778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-09. Verfasst von Xulei Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Disease, Second Hospital of Nanjing, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, People's Rep…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
As a natural compound present in a variety of plants, hispidulin has an inhibitory effect on tumors.
Methods
In this study, we combined network pharmacology, bioinformatics methods and experimental verification to explore the potential targets of hispidulin in inhibiting hepatocellular carcinoma.
Results
The network pharmacology analysis showed that the pharmacokinetic properties of hispidulin conformed to the Lipinski's five rules, and it had no hepatotoxicity, carcinogenicity, cytotoxicity, immunotoxicity, mutagenicity, and had the potential to be developed as a drug. The results of network pharmacology and bioinformatics analysis showed that hispidulin may interfere with the occurrence and progression of hepatocellular carcinoma by affecting CDK1, SRC, CCNB1, AURKB and PI3K/AKT signaling pathways. In vitro and in vivo studies, hispidulin inhibited the growth of hepatocellular carcinoma, induced apoptosis and inhibited migration of hepatocellular carcinoma cells and exhibited no significant toxicity to the normal tissues and organs of mice. It downregulated the expression of CDK1, CCNB1, SRC, AURKB protein and attenuated the PI3K/AKT pathway signal. These results suggest that hispidulin can exert anti-HCC effects through the PI3K/AKT pathway.
Conclusion
Hispidulin can inhibit the occurrence and progression of hepatocellular carcinoma through multiple targets, showing good anti-tumor efficacy in vitro and in vivo, and has the potential to develop new therapeutic drugs for hepatocellular carcinoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Liver Disease, Second Hospital of Nanjing, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
- Department of Liver Disease, Gaochun People's Hospital, Gaochun Hospital Affiliated to Jiangsu University, Nanjing, People's Republic of China.
- Department of pharmacy, Gaochun People's Hospital, Gaochun Hospital Affiliated to Jiangsu University, Nanjing, People's Republic of China.
Zitieren
APA
Zhang, X., Yang, Y., Xu, Z., Chen, M., Yang, A., & Yang, Y. (2026). Hispidulin Suppresses Hepatocellular Carcinoma Proliferation by Targeting PI3K-Akt Pathway: A Network Pharmacology and Experimental Validation Study. Journal of Hepatocellular Carcinoma, Volume 13, 1-15. https://doi.org/10.2147/jhc.s613778
Vancouver
Zhang X, Yang Y, Xu Z, Chen M, Yang A, Yang Y. Hispidulin Suppresses Hepatocellular Carcinoma Proliferation by Targeting PI3K-Akt Pathway: A Network Pharmacology and Experimental Validation Study. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-15. doi:10.2147/jhc.s613778
BibTeX
@article{Zhang2026,
author = {Zhang, Xulei and Yang, Yuan and Xu, Zhiyuan and Chen, Miaoyang and Yang, Anyin and Yang, Yongfeng},
title = {Hispidulin Suppresses Hepatocellular Carcinoma Proliferation by Targeting PI3K-Akt Pathway: A Network Pharmacology and Experimental Validation Study},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--15},
doi = {10.2147/jhc.s613778}
}
EUVIMED